Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
NCT02421380Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2015
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Hyperpolarized Pyruvate (13C) Injection + Gadolinium in malignant solid tumor, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Validation of HP MRI Reproducibility at 1 year. Started Apr 2015; status: recruiting.
02
Drugs
Hyperpolarized Pyruvate (13C) Injection + Gadolinium
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT02421380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421380.